Validation of Adapted Neutralization Assays Developed to Discriminate Anti-Rabies Virus Activity of Two Different Anti-Rabies Virus Monoclonal Antibodies Administered as a Combination

Autor: Arjen Companjen, Susan M. Moore, Bruno Boulanger, Stefan Kostense, Wilfred E. Marissen

Publikováno v: Biologics, Vol 3, Iss 1, Pp 11-22 (2023)

Assessment of rabies virus (RABV) neutralizing antibodies in subjects vaccinated or injected with anti-RABV immunoglobulins is central in determination of rabies protection. The rapid fluorescent focus inhibition test (RFFIT) is used for assessment o

Externí odkaz: https://doaj.org/article/3b1aac649a87409db31854b226524842

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Autor: Steven M. Albelda, Steef Engels, Soyeon Kim, Alla Volgina, Floris Fransen, Linda Johanna Aleida Hendriks, Cecile Geuijen, Shane Harvey, Horacio Nastri, Reid Huber, Leslie Hall, Gregory Hollis, John de Kruif, Jing Zhou, Abdul Basmeleh, Pieter Fokko Van Loo, Mark Throsby, Edmund K. Moon, Arjen Kramer, Willem Bartelink, Eric Rovers, Paul Tacken, Hans van der Maaden, Vanessa Zondag-van der Zande, Cheng Yen Huang, Rinse Klooster, Liang Chuan Wang, Ashwini Kulkarni, Chrysi Kanellopoulou, Marina Martinez, Wilfred E. Marissen, Shaun O'Brien, Alexander Berthold Hendrik Bakker, Ton Logtenberg, Renate den Blanken-Smit, Shaun Stewart, Peggy Scherle, Arpita Mondal, Patrick Mayes, Yao bin Liu, Thomas Condamine

Publikováno v: Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-19 (2021)

Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however, only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases anti-tumor activity preclinically, but attempts to translate these

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69ccb4c8aa2845dfcef907bf76c0bc4
http://europepmc.org/articles/PMC8295259

820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells

Autor: Cecile Geuijen, Floris Fransen, Renate den Blanken-Smit, Ton Logtenberg, Vanessa Zondag-van der Zande, Thomas Condamine, Arjen Kramer, Willem Bartelink, Mark Throsby, Pieter Fokko Van Loo, Liang-Chuan Wang, Yao-Bin Liu, Ashwini Kulkarni, Chrysi Kanellopoulou, Rinse Klooster, Simon Plyte, Wilfred E. Marissen, Linda Johanna Aleida Hendriks, Arpita Mondal, Abdul Basmeleh, Shane Harvey, Lex Bakker, Leslie Hall, Jing Zhou, Paul Tacken, Eric Rovers, Hans van der Maaden, Steef Engels, Shaun Stewart, Patrick Mayes, Cheng-Yen Huang, Alla Volgina, Horacio Nastri

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background MCLA-145 is a CD137 x PD-L1 bispecific antibody that releases PD-L1 mediated T-cell inhibition and activates and expands T cells through agonism of CD137. Immune checkpoint inhibitors (ICI) against PD-(L)1 have demonstrated anti-tumor effi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1182175d9e81f991933499ca20ee001a
https://doaj.org/article/3ac9962628b4422ba42992da2d11038e

A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis

Autor: Mark Throsby, Wilfred E. Marissen, John de Kruif, Alexander Berthold Hendrik Bakker, R. Arjen Kramer, Charles E. Rupprecht, Jaap Goudsmit

Publikováno v: Annual review of medicine. 58:359-368

The currently recommended treatment for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). This review sets out the criteria used to guide development of a cocktail of human monoclon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4eb1b9bcd5c39f55e17ba2f8496b2bc
https://doi.org/10.1146/annurev.med.58.061705.145053

Human monoclonal antibody combination against SARS coronavirus

Autor: Chung Y. Cheung, Freek Cox, Els van Deventer, Edward Norbert van den Brink, Arjen Q. Bakker, Leo L.M. Poon, Jaap Goudsmit, Hans Wilhelm Doerr, Jan ter Meulen, Wilfred E. Marissen, Wolfgang Preiser, John de Kruif, Vincent T. K. Chow, Johannes A. Bogaards, Cynthia S. W. Leung, Joseph S. M. Peiris

Publikováno v: PLoS Medicine
PLoS Medicine, Vol 3, Iss 7, p e237 (2006)
PLoS medicine, 3(7). Public Library of Science
PLoS Medicine, 3(7), 1071-1079. Public Library of Science
Ter Meulen, J, Van Den Brink, E N, Poon, L L M, Marissen, W E, Leung, C S W, Cox, F, Cheung, C Y, Bakker, A Q, Bogaards, J A, Van Deventer, E, Preiser, W, Doerr, H W, Chow, V T, De Kruif, J, Peiris, J S M & Goudsmit, J 2006, ' Human monoclonal antibody combination against SARS coronavirus : Synergy and coverage of escape mutants ', PLoS Medicine, vol. 3, no. 7, pp. 1071-1079 . https://doi.org/10.1371/journal.pmed.0030237

Background Experimental animal data show that protection against severe acute respiratory syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is feasible. For an effective immune prophylaxis in humans, broad coverage of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5133b48b4f0d835aa218c25329b9e0
https://doi.org/10.1371/journal.pmed.0030237